Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab +/- Apatinib in Advanced Endometrial Cancer
NCT06771154Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in endometrial cancer (EC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 36 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06771154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771154.